Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Select your state to see jurisdictional framework, reporting obligations, and authority links. Substance information above is the same in every state.
Focal onset seizures Clinical criteria: The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient, AND The condition must have failed to be controlled satisfactorily by at least one other antiseizure medication. Treatment criteria: Must be treated by a health practitioner who is any of: (i) a medical practitioner, (ii) an authorised PBS prescriber who is not a medical practitioner, but who is: (a) sharing care of the patient with at least one medical practitioner; (b) intending to share care of the patient with a medical practitioner.
“The mechanism of action is attributed to dose-dependent enzyme inhibition of GABA- transaminase (GABA-T) and consequent increased levels of the inhibitory neurotransmitter, GABA.”
“Vigabatrin is eliminated from the plasma with a terminal half life of 5-8 hours with approximately 70% of a single oral dose being recovered in the urine as unchanged drug in the first 24 hours post-dose.”
Working under the parallel aged-care framework? Aged-care equivalent →
Curated subset. The full adverse-effect list is in the TGA Product Information; click any citation above to open it.
“Vigabatrin does not induce the hepatic cytochrome P450 enzymes nor is it extensively metabolised or plasma-protein bound, therefore drug interactions are unlikely.”